|
Volumn 157, Issue 2, 2010, Pages 179-180
|
Congenital cytomegalovirus infection: Screening and treatment
|
Author keywords
[No Author keywords available]
|
Indexed keywords
GANCICLOVIR;
MONOCLONAL ANTIBODY;
VALGANCICLOVIR;
VIRUS DNA;
ANTIVIRUS AGENT;
ANTIVIRAL THERAPY;
CHICKENPOX;
CHORIORETINITIS;
CLINICAL TRIAL;
CONGENITAL INFECTION;
CYTOMEGALOVIRUS INFECTION;
DIAGNOSTIC TEST;
DISEASE SURVEILLANCE;
DRUG ABSORPTION;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG EFFICACY;
EDITORIAL;
EYE EXAMINATION;
FOLLOW UP;
HEARING IMPAIRMENT;
HEARING LOSS;
HUMAN;
IMMUNIZATION;
IMMUNOCOMPROMISED PATIENT;
NEWBORN SCREENING;
POLYMERASE CHAIN REACTION;
PRIORITY JOURNAL;
RETINITIS;
TREATMENT DURATION;
VIREMIA;
VIRUS CULTURE;
VIRUS REPLICATION;
METHODOLOGY;
NEWBORN;
NOTE;
PEDIATRICS;
PERCEPTION DEAFNESS;
TIME;
TREATMENT OUTCOME;
ANTIVIRAL AGENTS;
CLINICAL TRIALS AS TOPIC;
CYTOMEGALOVIRUS INFECTIONS;
GANCICLOVIR;
HEARING LOSS, SENSORINEURAL;
HUMANS;
INFANT, NEWBORN;
NEONATAL SCREENING;
PEDIATRICS;
TIME FACTORS;
TREATMENT OUTCOME;
|
EID: 77955301806
PISSN: 00223476
EISSN: None
Source Type: Journal
DOI: 10.1016/j.jpeds.2010.04.045 Document Type: Editorial |
Times cited : (9)
|
References (8)
|